高血圧治療薬市場、シェア、規模、動向、産業分析レポート：病態別、タイプ別、推進剤別、流通チャネル別、薬物タイプ別、地域別、セグメント予測、2024年～2023年

Polaris Market Research社の最新調査によると、世界の高血圧治療薬市場規模は2032年までに346億4,610万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

高血圧症治療薬市場は、重大な健康問題としての高血圧症に対する意識の高まりや、世界のヘルスケアサービスへのアクセスの改善もあり、大幅な成長を遂げています。この動向は、降圧薬の需要を刺激する上で極めて重要です。というのも、認知度の向上と医療アクセスの改善は、心血管疾患の主要な危険因子である高血圧の診断と管理に直接影響するからです。

高血圧症（しばしば高血圧ともよばれる）に対する意識は、一般人口や医療従事者の間で著しく高まっています。このような意識の高まりは、広範な公衆衛生キャンペーン、教育プログラム、および心血管疾患と闘うことを目的とした政府や非政府組織によるイニシアチブの結果です。こうした取り組みにより、脳卒中、心臓発作、腎不全など、高血圧に関連するリスクに対する認識が高まり、血圧値の積極的な管理が奨励されるようになりました。意識が高まるにつれて、高血圧について医師の診断を受ける人が増え、降圧剤の需要に直接影響を与える可能性があります。

高血圧治療薬市場を牽引するヘルスケア・アクセスの役割は、誇張しすぎることはないです。最近の動向では、特に発展途上国において、ヘルスケア・インフラの整備が世界的に進められています。これには、ヘルスケア施設の拡大、医療従事者の増加、国民皆保険制度の導入などが含まれます。このような発展により、ヘルスケア・サービスがより多くの人々にとって利用しやすくなり、高血圧の診断と治療の可能性が高まっています。高血圧を早期に効果的に管理することで、重篤な合併症を発症するリスクが大幅に低下し、降圧薬の使用が必要となります。

遠隔医療やデジタルヘルスプラットフォームも、ヘルスケアへのアクセスを強化する上で極めて重要な役割を果たしています。これらの技術により、遠隔地や十分なサービスを受けていない地域の患者でも、医療提供者と相談したり、健康教育を受けたり、高血圧のような慢性疾患を管理したりすることが可能になりました。遠隔医療サービスの利便性と効率性により、これらのプラットフォームが広く採用されるようになり、より多くの患者がタイムリーな診断と処方を受けることで、高血圧治療薬の需要がさらに高まっています。

さらに、高血圧管理がプライマリ・ヘルスケアの環境に統合されたことは、ヘルスケア・アクセスを改善する重要な要因となっています。プライマリ・ケアの開業医は、健康上の不安を抱えた人が最初に接触する窓口であることが多く、高血圧の早期発見と管理に役立っています。血圧スクリーニングを定期的な受診に組み込むことで、ヘルスケア・システムは高血圧をより効果的に特定し、治療することができます。

高血圧の世界の負担は、公衆衛生上の差し迫った課題であり、この疾患は世界の疾病負担の主な原因となっています。血圧がコントロールされないことの意味について社会がより深く知るようになり、ヘルスケアシステムがより包括的で利用しやすいものに進化するにつれて、高血圧治療薬の需要は増加すると予想されます。予防ヘルスケアと慢性疾患の管理が重視されるようになり、効果的な降圧薬の必要性がさらに高まっています。

高血圧治療薬市場レポートハイライト

2023年には、アンジオテンシン変換酵素（A.C.E.）阻害薬セグメントが高血圧治療薬市場で最大の市場シェアを占めました。重大な副作用を伴わない長期的な高血圧管理に有効であることから、慢性治療薬として好まれています。

小売薬局セグメントは、予測期間中に最も速いCAGRで成長すると予想されます。小売薬局は、血圧モニタリング、健康診断、慢性疾患管理プログラムなどのサービスを提供することが増えており、高血圧患者にとって重要な接点となっています。

2023年には、北米が最大市場を占めました。北米の高齢化は高血圧治療薬市場に大きく寄与しています。高血圧の有病率は年齢とともに増加し、米国国勢調査局は、2030年までにベビーブーム世代がすべて65歳以上になると予測しており、高血圧治療薬の需要がさらに高まるとみています。

アジア太平洋地域は、高血圧治療薬市場において最も速いCAGRで成長すると予想されています。経済成長とヘルスケア支出の増加：多くのアジア太平洋諸国では経済成長によりヘルスケア支出が増加しています。これにより、ヘルスケア・インフラへの投資が拡大し、高血圧治療薬を含む幅広い医薬品へのアクセスが可能になりました。

世界の主要市場プレイヤーは、Takeda Pharmaceutical Company Limited.、AstraZeneca、Teva Pharmaceutical Industries Ltd、Abbott, Pfizer Inc.、Novartis AG, Merck KGaA、Johnson & Johnson Services, Inc.、Gilead Sciences, Inc.、Sanofi S.A.、Bayer AGです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の高血圧治療薬市場の洞察

• 高血圧治療薬- 業界スナップショット
• 高血圧治療薬市場力学
  • 促進要因と機会
    • 世界中で高血圧症の罹患率が増加しており、薬剤需要が増加すると予測される
    • 高血圧が重大な健康問題であるという認識の高まりとヘルスケアサービスへのアクセスの改善
  • 抑制要因と課題
    • 特許の有効期限
• PESTLE分析
• 高血圧治療薬業界の動向
• バリューチェーン分析
• COVID-19の影響分析

第5章 世界の高血圧治療薬市場：病態別

• 主な調査結果
• イントロダクション
• 一次
• 二次

第6章 世界の高血圧治療薬市場：流通チャネル別

• 主な調査結果
• イントロダクション
• 小売薬局
• eコマース薬局
• 病院薬局

第7章 世界の高血圧治療薬市場：タイプ別

• 主な調査結果
• イントロダクション
• 利尿剤
• アルファ遮断薬
• カルシウムチャネル遮断薬
• ベータ遮断薬
• アンジオテンシン変換酵素（ACE）阻害剤
• 血管拡張薬
• その他

第8章 世界の高血圧治療薬市場：治療薬タイプ別

• 主な調査結果
• イントロダクション
• 併用療法
• 単独療法
• 固定用量の組み合わせ

第9章 世界の高血圧治療薬市場：地域

• 主な調査結果
• イントロダクション
  • 高血圧治療薬市場評価：地域別、2019年～2032年
• 北米
  • 北米：病態別、2019年～2032年
  • 北米：治療薬タイプ別、2019年～2032年
  • 北米：流通チャネル別、2019年～2032年
  • 北米：タイプ別、2019年～2032年
  • 米国
  • カナダ
• 欧州
  • 欧州：病態別、2019年～2032年
  • 欧州：治療薬タイプ別、2019年～2032年
  • 欧州：流通チャネル別、2019年～2032年
  • 欧州：タイプ別、2019年～2032年
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • オランダ
  • ロシア
• アジア太平洋地域
  • アジア太平洋地域：病態別、2019年～2032年
  • アジア太平洋地域：治療薬タイプ別、2019年～2032年
  • アジア太平洋地域：流通チャネル別、2019年～2032年
  • アジア太平洋：タイプ別、2019年～2032年
  • 中国
  • インド
  • 日本
  • マレーシア
  • インドネシア
  • 韓国
• 中東・アフリカ
  • 中東・アフリカ：病態別、2019年～2032年
  • 中東およびアフリカ：治療薬タイプ別、2019年～2032年
  • 中東・アフリカ：流通チャネル別、2019年～2032年
  • 中東・アフリカ：タイプ別、2019年～2032年
  • サウジアラビア
  • 南アフリカ
  • イスラエル
  • アラブ首長国連邦
• ラテンアメリカ
  • ラテンアメリカ：病態別、2019年～2032年
  • ラテンアメリカ：治療薬タイプ別、2019年～2032年
  • ラテンアメリカ：流通チャネル別、2019年～2032年
  • ラテンアメリカ：タイプ別、2019年～2032年
  • メキシコ
  • ブラジル
  • アルゼンチン

第10章 競合情勢

• 拡大と買収の分析
  • 拡大
  • 買収
• 提携/協業/合意/公開

第11章 企業プロファイル

• Takeda Pharmaceutical Company Limited
• AstraZeneca
• Teva Pharmaceutical Industries Ltd
• Abbott
• Pfizer Inc
• Novartis AG
• Merck KGaA
• Johnson & Johnson Services, Inc
• Gilead Sciences, Inc
• Sanofi S.A
• Bayer AG

List of Tables

• Table 1 Global Hypertension Drug Market, by Condition, by Region, 2019-2032 (USD Million)
• Table 2 Global Hypertension Drug Market, by Distribution Channel, by Region, 2019-2032 (USD Million)
• Table 3 Global Hypertension Drug Market, by Type, by Region, 2019-2032 (USD Million)
• Table 4 Global Hypertension Drug Market, by Medication Type, by Region, 2019-2032 (USD Million)
• Table 5 Hypertension Drug Market Assessment, By Geography, 2019-2032 (USD Million)
• Table 6 North America: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 7 North America: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 8 North America: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 9 North America: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 10 U.S.: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 11 U.S.: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 12 U.S.: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 13 U.S.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 14 Canada: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 15 Canada: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 16 Canada: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 17 Canada: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 18 Europe: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 19 Europe: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 20 Europe: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 21 Europe: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 22 Germany: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 23 Germany: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 24 Germany: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 25 Germany: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 26 France: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 27 France: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 28 France: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 29 France: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 30 UK: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 31 UK: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 32 UK: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 33 UK: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 34 Italy: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 35 Italy: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 36 Italy: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 37 Italy: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 38 Netherlands: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 39 Netherlands: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 40 Netherlands: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 41 Netherlands: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 42 Spain: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 43 Spain: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 44 Spain: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 45 Spain: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 46 Russia: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 47 Russia: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 48 Russia: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 49 Russia: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 50 Asia Pacific: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 51 Asia Pacific: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 52 Asia Pacific: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 53 Asia Pacific: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 54 China: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 55 China: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 56 China: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 57 China: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 58 Japan: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 59 Japan: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 60 Japan: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 61 Japan: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 62 India: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 63 India: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 64 India: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 65 India: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 66 Indonesia: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 67 Indonesia: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 68 Indonesia: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 69 Indonesia: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 70 Malaysia: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 71 Malaysia: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 72 Malaysia: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 73 Malaysia: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 74 South Korea: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 75 South Korea: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 76 South Korea: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 77 South Korea: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 78 Latin America: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 79 Latin America: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 80 Latin America: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 81 Latin America: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 82 Brazil: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 83 Brazil: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 84 Brazil: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 85 Brazil: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 86 Mexico: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 87 Mexico: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 88 Mexico: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 89 Mexico: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 90 Argentina: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 91 Argentina: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 92 Argentina: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 93 Argentina: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 94 Middle East & Africa: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 95 Middle East & Africa: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 96 Middle East & Africa: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 97 Middle East & Africa: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 98 UAE: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 99 UAE: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 100 UAE: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 101 UAE: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 102 Saudi Arabia: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 103 Saudi Arabia: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 104 Saudi Arabia: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 105 Saudi Arabia: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 106 South Africa: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 107 South Africa: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 108 South Africa: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 109 South Africa: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• Table 110 Israel: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• Table 111 Israel: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• Table 112 Israel: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• Table 113 Israel: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)

List of Figures

• Figure 1. Global Hypertension Drug Market, 2019-2032 (USD Million)
• Figure 2. Integrated Ecosystem
• Figure 3. Research Methodology: Top-Down & Bottom-Up Medication Type
• Figure 4. Market by Geography
• Figure 5. Porter's Five Forces
• Figure 6. Market by Condition
• Figure 7. Global Hypertension Drug Market, by Condition, 2021 & 2030 (USD Million)
• Figure 8. Market by Medication Type
• Figure 9. Global Hypertension Drug Market, by Medication Type, 2021 & 2030 (USD Million)
• Figure 10. Market by Distribution Channel
• Figure 11. Global Hypertension Drug Market, by Distribution Channel, 2021 & 2030 (USD Million)
• Figure 12. Market by Type
• Figure 13. Global Hypertension Drug Market, by Type, 2021 & 2030 (USD Million)
• Figure 14. Hypertension Drug Market Assessment, By Geography, 2019-2032 (USD Million)
• Figure 15. Strategic Analysis - Hypertension Drug Market

The global hypertension drug market size is expected to reach USD 34,646.10 Million by 2032, according to a new study by Polaris Market Research. The report "Hypertension Drug Market Share, Size, Trends, Industry Analysis Report, By Condition (Primary, Secondary); By Type; By Propulsion; By Distribution Channel; By Medication Type; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The hypertension drugs market is experiencing substantial growth, driven in part by the rising awareness of hypertension as a critical health issue and improved access to healthcare services worldwide. This trend is crucial in stimulating demand for antihypertensive medications, as increased awareness and healthcare access directly influence the diagnosis and management of hypertension, a major risk factor for cardiovascular diseases.

Awareness of hypertension, often referred to as high blood pressure, has significantly increased among the general population and healthcare professionals. This heightened awareness is the result of extensive public health campaigns, educational programs, and initiatives by governments and non-governmental organizations aimed at combating cardiovascular diseases. These efforts have made individuals more cognizant of the risks associated with high blood pressure, including stroke, heart attack, and kidney failure, thereby encouraging proactive management of blood pressure levels. As awareness grows, more individuals are likely to seek medical advice for hypertension, directly impacting the demand for antihypertensive drugs.

The role of healthcare access in driving the hypertension drugs market cannot be overstated. In recent years, there has been a global push towards improving healthcare infrastructure, particularly in developing countries. This includes the expansion of healthcare facilities, increased availability of healthcare professionals, and the implementation of universal health coverage schemes. Such developments have made healthcare services more accessible to a larger segment of the population, thereby increasing the likelihood of hypertension diagnosis and treatment. Early and effective management of hypertension significantly reduces the risk of developing severe complications, necessitating the use of antihypertensive medications.

Telemedicine and digital health platforms have also played a pivotal role in enhancing healthcare access. These technologies have made it possible for patients in remote or underserved areas to consult with healthcare providers, receive health education, and manage chronic conditions like hypertension. The convenience and efficiency of telehealth services have led to wider adoption of these platforms, further driving the demand for hypertension medications as more individuals receive timely diagnoses and prescriptions.

Moreover, the integration of hypertension management into primary healthcare settings has been a significant factor in improving healthcare access. Primary care practitioners are often the first point of contact for individuals with health concerns, making them instrumental in the early detection and management of hypertension. By integrating blood pressure screening into routine healthcare visits, healthcare systems can identify and treat hypertension more effectively, thereby increasing the demand for antihypertensive medications.

The global burden of hypertension is a pressing public health challenge, with the condition being a major contributor to the global disease burden. As societies become more informed about the implications of uncontrolled blood pressure and as healthcare systems evolve to become more inclusive and accessible, the demand for hypertension drugs is expected to rise. The growing emphasis on preventive healthcare and the management of chronic conditions further underscores the need for effective antihypertensive medications.

Hypertension Drug Market Report Highlights

In 2023, the angiotensin-converting enzyme (A.C.E.) inhibitors segment accounted for the largest market share in the hypertension drug market. Their efficacy in the long-term management of hypertension without significant adverse effects makes them a preferred choice for chronic therapy.

The retail pharmacies segment is expected to grow at the fastest CAGR during the forecast period. Retail pharmacies increasingly offer services such as blood pressure monitoring, health screenings, and chronic disease management programs, making them a key point of contact for hypertension patients.

In 2023, North America dominated the largest market. The aging population in North America significantly contributes to the hypertension drug market. Hypertension prevalence increases with age, and the U.S. Census Bureau projects that by 2030, all baby boomers will be age 65 or older, further increasing the demand for hypertension medications.

Asia Pacific is expected to grow at the fastest CAGR in Hypertension Drug market. Economic Growth and Rising Healthcare Expenditure: Economic growth in many Asia Pacific countries has led to increased healthcare expenditure. This allows for greater investment in healthcare infrastructure and access to a wider range of medications, including those for hypertension.

The global key market players are Takeda Pharmaceutical Company Limited., AstraZeneca, Teva Pharmaceutical Industries Ltd, Abbott, Pfizer Inc., Novartis AG, Merck KGaA, Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Sanofi S.A., Bayer AG.

Polaris Market Research has segmented the hypertension drug market repair report based on condition, type, distribution channel, medication type, and region.

Hypertension Drug, Condition Outlook (Revenue - USD Million, 2019 - 2032)

• Primary
• Secondary

Hypertension Drug, Type Outlook (Revenue - USD Million, 2019 - 2032)

• Diuretics
• Alpha-Blockers
• Calcium Channel Blockers
• Beta blockers
• Angiotensin-Converting Enzyme (A.C.E.) Inhibitors
• Vasodilators
• Others

Hypertension Drug, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

• Retail Pharmacies
• E-Commerce Pharmacies
• Hospital Pharmacies

Hypertension Drug, Medication Type Outlook (Revenue - USD Million, 2019 - 2032)

• Combination Therapy
• Monotherapy
• Fixed Dose Combinations

Hypertension Drug, Regional Outlook (Revenue - USD Million, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Australia
• Rest of Asia Pacific
• Latin America
• Argentina
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of Middle East & Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Hypertension Drug Market Insights

• 4.1. Hypertension Drug - Industry Snapshot
• 4.2. Hypertension Drug Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing prevalence of hypertension worldwide have been projected to spur drug demand
    • 4.2.1.2. Rising awareness of hypertension as a critical health issue and improved access to healthcare services
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Patent expirations
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTLE Analysis
• 4.5. Hypertension Drug Industry Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Hypertension Drug Market, by Condition

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
• 5.3. Primary
  • 5.3.1. Global Hypertension Drug Market, by Primary, by Region, 2019-2032 (USD Million)
• 5.4. Secondary
  • 5.4.1. Global Hypertension Drug Market, by Secondary, by Region, 2019-2032 (USD Million)

6. Global Hypertension Drug Market, by Distribution Channel

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
• 6.3. Retail Pharmacies
  • 6.3.1. Global Hypertension Drug Market, by Retail Pharmacies, by Region, 2019-2032 (USD Million)
• 6.4. E-Commerce Pharmacies
  • 6.4.1. Global Hypertension Drug Market, by E-Commerce Pharmacies, by Region, 2019-2032 (USD Million)
• 6.5. Hospital Pharmacies
  • 6.5.1. Global Hypertension Drug Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Million)

7. Global Hypertension Drug Market, by Type

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• 7.3. Diuretics
  • 7.3.1. Global Hypertension Drug Market, by Diuretics, by Region, 2019-2032 (USD Million)
• 7.4. Alpha-Blockers
  • 7.4.1. Global Hypertension Drug Market, by Alpha-Blockers, by Region, 2019-2032 (USD Million)
• 7.5. Calcium Channel Blockers
  • 7.5.1. Global Hypertension Drug Market, by Calcium Channel Blockers, by Region, 2019-2032 (USD Million)
• 7.6. Beta blockers
  • 7.6.1. Global Hypertension Drug Market, by Beta blockers, by Region, 2019-2032 (USD Million)
• 7.7. Angiotensin-Converting Enzyme (A.C.E.) Inhibitors
  • 7.7.1. Global Hypertension Drug Market, by Angiotensin-Converting Enzyme (A.C.E.) Inhibitors, by Region, 2019-2032 (USD Million)
• 7.8. Vasodilators
  • 7.8.1. Global Hypertension Drug Market, by Vasodilators, by Region, 2019-2032 (USD Million)
• 7.9. Others
  • 7.9.1. Global Other Hypertension Drug Market, by Region, 2019-2032 (USD Million)

8. Global Hypertension Drug Market, by Medication Type

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
• 8.3. Combination Therapy
  • 8.3.1. Global Hypertension Drug Market, by Combination Therapy, by Region, 2019-2032 (USD Million)
• 8.4. Monotherapy
  • 8.4.1. Global Hypertension Drug Market, by Monotherapy, by Region, 2019-2032 (USD Million)
• 8.5. Fixed Dose Combinations
  • 8.5.1. Global Hypertension Drug Market, by Fixed Dose Combinations, by Region, 2019-2032 (USD Million)

9. Global Hypertension Drug Market, by Geography

• 9.1. Key findings
• 9.2. Introduction
  • 9.2.1. Hypertension Drug Market Assessment, By Geography, 2019-2032 (USD Million)
• 9.3. Hypertension Drug Market - North America
  • 9.3.1. North America: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  • 9.3.2. North America: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  • 9.3.3. North America: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  • 9.3.4. North America: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.3.5. Hypertension Drug Market - U.S.
    • 9.3.5.1. U.S.: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.3.5.2. U.S.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.3.5.3. U.S.: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.3.5.4. U.S.: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.3.6. Hypertension Drug Market - Canada
    • 9.3.6.1. Canada: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.3.6.2. Canada: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.3.6.3. Canada: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.3.6.4. Canada: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• 9.4. Hypertension Drug Market - Europe
  • 9.4.1. Europe: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  • 9.4.2. Europe: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  • 9.4.3. Europe: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  • 9.4.4. Europe: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.4.5. Hypertension Drug Market - UK
    • 9.4.5.1. UK: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.4.5.2. UK: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.4.5.3. UK: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.4.5.4. UK: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.4.6. Hypertension Drug Market - France
    • 9.4.6.1. France: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.4.6.2. France: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.4.6.3. France: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.4.6.4. France: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.4.7. Hypertension Drug Market - Germany
    • 9.4.7.1. Germany: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.4.7.2. Germany: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.4.7.3. Germany: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.4.7.4. Germany: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.4.8. Hypertension Drug Market - Italy
    • 9.4.8.1. Italy: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.4.8.2. Italy: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.4.8.3. Italy: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.4.8.4. Italy: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.4.9. Hypertension Drug Market - Spain
    • 9.4.9.1. Spain: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.4.9.2. Spain: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.4.9.3. Spain: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.4.9.4. Spain: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.4.10. Hypertension Drug Market - Netherlands
    • 9.4.10.1. Netherlands: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.4.10.2. Netherlands: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.4.10.3. Netherlands: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.4.10.4. Netherlands: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.4.11. Hypertension Drug Market - Russia
    • 9.4.11.1. Russia: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.4.11.2. Russia.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.4.11.3. Russia: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.4.11.4. Russia: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• 9.5. Hypertension Drug Market - Asia Pacific
  • 9.5.1. Asia Pacific: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  • 9.5.2. Asia Pacific: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  • 9.5.3. Asia Pacific: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  • 9.5.4. Asia Pacific: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.5.5. Hypertension Drug Market - China
    • 9.5.5.1. China: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.5.5.2. China.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.5.5.3. China: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.5.5.4. China: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.5.6. Hypertension Drug Market - India
    • 9.5.6.1. India: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.5.6.2. India.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.5.6.3. India: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.5.6.4. India: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.5.7. Hypertension Drug Market - Japan
    • 9.5.7.1. Japan: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.5.7.2. Japan.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.5.7.3. Japan: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.5.7.4. Japan: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.5.8. Hypertension Drug Market - Malaysia
    • 9.5.8.1. Malaysia: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.5.8.2. Malaysia.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.5.8.3. Malaysia: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.5.8.4. Malaysia: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.5.9. Hypertension Drug Market - Indonesia
    • 9.5.9.1. Indonesia: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.5.9.2. Indonesia.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.5.9.3. Indonesia: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.5.9.4. Indonesia: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.5.10. Hypertension Drug Market - South Korea
    • 9.5.10.1. South Korea: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.5.10.2. South Korea.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.5.10.3. South Korea: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.5.10.4. South Korea: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• 9.6. Hypertension Drug Market - Middle East & Africa
  • 9.6.1. Middle East & Africa: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  • 9.6.2. Middle East & Africa: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  • 9.6.3. Middle East & Africa: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  • 9.6.4. Middle East & Africa: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.6.5. Hypertension Drug Market - Saudi Arabia
    • 9.6.5.1. Saudi Arabia: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.6.5.2. Saudi Arabia: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.6.5.3. Saudi Arabia: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.6.5.4. Saudi Arabia: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.6.6. Hypertension Drug Market - South Africa
    • 9.6.6.1. South Africa: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.6.6.2. South Africa: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.6.6.3. South Africa: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.6.6.4. South Africa: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.6.7. Hypertension Drug Market - Israel
    • 9.6.7.1. Israel: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.6.7.2. Israel: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.6.7.3. Israel: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.6.7.4. Israel: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.6.8. Hypertension Drug Market - UAE
    • 9.6.8.1. UAE: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.6.8.2. UAE: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.6.8.3. UAE: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.6.8.4. UAE: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
• 9.7. Hypertension Drug Market - Latin America
  • 9.7.1. Latin America: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  • 9.7.2. Latin America: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  • 9.7.3. Latin America: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  • 9.7.4. Latin America: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.7.5. Hypertension Drug Market - Mexico
    • 9.7.5.1. Mexico: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.7.5.2. Mexico: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.7.5.3. Mexico: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.7.5.4. Mexico: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.7.6. Hypertension Drug Market - Brazil
    • 9.7.6.1. Brazil: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.7.6.2. Brazil: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.7.6.3. Brazil: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.7.6.4. Brazil: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
  • 9.7.7. Hypertension Drug Market - Argentina
    • 9.7.7.1. Argentina: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
    • 9.7.7.2. Argentina: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
    • 9.7.7.3. Argentina: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.7.7.4. Argentina: Hypertension Drug Market, by Type, 2019-2032 (USD Million)

10. Competitive Landscape

• 10.1. Expansion and Acquisition Analysis
  • 10.1.1. Expansion
  • 10.1.2. Acquisitions
• 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

• 11.1. Takeda Pharmaceutical Company Limited
  • 11.1.1. Company Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Benchmarking
  • 11.1.4. Recent Development
• 11.2. AstraZeneca
  • 11.2.1. Company Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Benchmarking
  • 11.2.4. Recent Development
• 11.3. Teva Pharmaceutical Industries Ltd
  • 11.3.1. Company Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Benchmarking
  • 11.3.4. Recent Development
• 11.4. Abbott
  • 11.4.1. Company Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Benchmarking
  • 11.4.4. Recent Development
• 11.5. Pfizer Inc
  • 11.5.1. Company Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Benchmarking
  • 11.5.4. Recent Development
• 11.6. Novartis AG
  • 11.6.1. Company Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Benchmarking
  • 11.6.4. Recent Development
• 11.7. Merck KGaA
  • 11.7.1. Company Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Benchmarking
  • 11.7.4. Recent Development
• 11.8. Johnson & Johnson Services, Inc
  • 11.8.1. Company Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Benchmarking
  • 11.8.4. Recent Development
• 11.9. Gilead Sciences, Inc
  • 11.9.1. Company Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Benchmarking
  • 11.9.4. Recent Development
• 11.10. Sanofi S.A
  • 11.10.1. Company Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Benchmarking
  • 11.10.4. Recent Development
• 11.11. Bayer AG
  • 11.11.1. Company Overview
  • 11.11.2. Financial Performance
  • 11.11.3. Product Benchmarking
  • 11.11.4. Recent Development